A detailed history of D. E. Shaw & Co., Inc. transactions in G1 Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 767,066 shares of GTHX stock, worth $5.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
767,066
Previous 785,259 2.32%
Holding current value
$5.48 Million
Previous $3.39 Million 48.47%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.2 - $4.98 $40,024 - $90,601
-18,193 Reduced 2.32%
767,066 $1.75 Million
Q1 2024

May 15, 2024

BUY
$2.1 - $4.83 $608,596 - $1.4 Million
289,808 Added 58.49%
785,259 $3.39 Million
Q4 2023

Feb 14, 2024

SELL
$1.12 - $3.73 $10,786 - $35,923
-9,631 Reduced 1.91%
495,451 $1.51 Million
Q3 2023

Nov 14, 2023

SELL
$1.22 - $2.67 $135,933 - $297,494
-111,421 Reduced 18.07%
505,082 $727,000
Q2 2023

Aug 14, 2023

BUY
$2.46 - $3.14 $459,685 - $586,752
186,864 Added 43.49%
616,503 $1.54 Million
Q1 2023

May 15, 2023

SELL
$2.57 - $8.16 $38,724 - $122,954
-15,068 Reduced 3.39%
429,639 $1.15 Million
Q4 2022

Feb 14, 2023

BUY
$5.19 - $13.5 $1.82 Million - $4.72 Million
349,733 Added 368.24%
444,707 $2.41 Million
Q3 2022

Nov 14, 2022

SELL
$5.17 - $16.99 $217,165 - $713,664
-42,005 Reduced 30.67%
94,974 $1.19 Million
Q2 2022

Aug 15, 2022

BUY
$4.04 - $8.51 $553,395 - $1.17 Million
136,979 New
136,979 $677,000
Q1 2021

May 17, 2021

SELL
$17.58 - $32.59 $307,034 - $569,184
-17,465 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$10.99 - $20.4 $191,940 - $356,286
17,465 New
17,465 $314,000
Q2 2020

Aug 14, 2020

SELL
$9.57 - $24.37 $490,778 - $1.25 Million
-51,283 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$9.07 - $26.32 $465,136 - $1.35 Million
51,283 New
51,283 $565,000

Others Institutions Holding GTHX

About G1 Therapeutics, Inc.


  • Ticker GTHX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,746,800
  • Market Cap $306M
  • Description
  • G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...
More about GTHX
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.